Inhibitors of HIV-1 protease: 10 years after
- 26 July 2006
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 16 (8) , 1067-1091
Abstract
Highly active antiretroviral therapy (HAART) has dramatically changed the course of HIV infection. This therapy involves the use of at least three agents from two distinct classes of antivirals: a ...Keywords
This publication has 74 references indexed in Scilit:
- Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic OutcomeCurrent Pharmaceutical Design, 2005
- New Approaches toward Anti-HIV ChemotherapyJournal of Medicinal Chemistry, 2005
- HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradationNature Medicine, 2003
- The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 VifNature Medicine, 2003
- Anticancer and Antiviral SulfonamidesCurrent Medicinal Chemistry, 2003
- The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNANature, 2003
- Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapyNature Medicine, 2002
- Strategies in the design of antiviral drugsNature Reviews Drug Discovery, 2002
- New Developments in Anti-HIV ChemotherapyCurrent Medicinal Chemistry, 2001
- HIV chemotherapyNature, 2001